From Indystar.com: A third set of clinical trials to seek a drug to delay the progression of mild to moderate Alzheimer’s disease is about to get underway, drugmaker Eli Lilly and Co. said today. The Indianapolis company will begin enrolling patients this month in two separate but identical Phase III clinical trials of Solanezumab, an [...]
{ 0 comments }

